Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 17/20 | 0.50 |
| ▸ | LATS2 | Q9NRM7 | 12/20 | 0.50 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.44 |
| ▸ | AOC1 | P19801 | 2/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL802293 | 0.88 | HIPK2 (0.44) | LATS1LATS2HIPK2AOC1AOC3 | |
| SCHEMBL13107477 | 0.86 | LATS1 (0.45) | LATS1LATS2 | |
| SCHEMBL13437973 | 0.83 | LATS1 (0.51) | LATS1LATS2HIPK2AOC1AOC3 | |
| SCHEMBL19249825 | 0.79 | LATS1 (0.42) | LATS1LATS2 | |
| SCHEMBL21027635 | 0.75 | LATS1 (0.43) | LATS1LATS2 | |
| SCHEMBL23717024 | 0.74 | MAOA (0.43) | LATS1LATS2 | |
| SCHEMBL801649 | 0.74 | LATS1 (0.50) | LATS1LATS2HIPK2AOC1AOC3 | |
| SCHEMBL801807 | 0.74 | HIPK2 (0.45) | LATS1LATS2HIPK2AOC1AOC3 | |
| SCHEMBL801653 | 0.73 | LMNA (0.31) | — | |
| SCHEMBL801991 | 0.71 | LATS1 (0.65) | LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-7691853-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-7473691-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-06 | — | — | US | disclosed |
| US-7390815-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-24 | — | — | US | disclosed |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | LATS1 318/4885LATS2 325/4885HIPK2 185/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | LATS1 1086/4885LATS2 1373/4885HIPK2 410/4885 |
| US-20070270444-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, CDK3, GSK3A | LATS1 318/4885LATS2 325/4885HIPK2 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.